Soleno Therapeutics Inc.
Soleno Therapeutics Announces Investor Roadshow and Launch of VYKAT XR
Summary
Soleno Therapeutics, Inc. (NASDAQ: SLNO) announced that senior management will participate in a non-deal roadshow hosted by Guggenheim Securities and Piper Sandler during August 18-19, 2025. The Company will also launch VYKAT XR, the first FDA-approved treatment for hyperphagia in patients with Prader-Willi Syndrome (PWS) aged 4 years and older. VYKAT XR, approved on March 26, 2025, demonstrated significant reductions in hyperphagia in clinical trials. The launch is supported by a strong commercial strategy targeting pediatric and adult endocrinologists, with a significant commercial opportunity in the U.S. PWS market estimated at ~10,000 people. The Company has a robust balance sheet with pro forma cash of ~$510 million as of June 2025, sufficient to fund operations well into the commercial launch.
Profitelligence Alerts
Get alerts for SLNO
Be first to know when Soleno Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Soleno Therapeutics Inc.
Soleno Therapeutics Inc. is a biopharmaceutical company dedicated to the development and commercialization of novel therapeutics for rare diseases. Its primary focus lies on the treatment of genetic disorders that have a significant medical need, such as Prader-Willi syndrome, a complex condition that affects the musculoskeletal and endocrine systems. Soleno is committed to pioneering advancements in the pharmaceutical industry by leveraging innovative approaches to drug development. The company's lead treatment candidate, rooted in addressing metabolic and neurobehavioral abnormalities, plays a critical role within its pipeline. Soleno's research and development efforts are concentrated on improving patient outcomes through therapies that target underlying disease mechanisms. Based in Redwood City, California, Soleno Therapeutics Inc. actively collaborates with scientific communities and healthcare providers to enhance its therapeutic offerings. In the financial market, Soleno Therapeutics is notably positioned as part of the healthcare and biotechnology sectors, reflecting its significance in developing treatments that can transform patient care and address unmet medical needs in niche and complex disease areas.
Official SEC Documents
Advertisement